Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cardiovascular Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRKD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Active Enzyme | Active PRKD1 Kinase Domain (wild-type and D765N mutant). High purity (>95%), ATP-binding competent, endotoxin <1EU/ug. Sequence verified. | View PRKD1 Products |
| Gene Delivery | PRKD1 Promise-ORF / Lentivirus with GFP reporter for stable cell line construction. | View PRKD1 Products |
| Benchmark Ab | Anti-PRKD1 (Phospho-Ser916) recombinant rabbit monoclonal for activation state detection (western blot, IHC). | View PRKD1 Products |
| Validator | PRKD1 siRNA Set (3 unique sequences) for knockdown verification and assay specificity control. | View PRKD1 Products |
| Related Target | PRKD2 – Isoform homology screening (64% identity) for selectivity assays. | View PRKD2 Products |
| Related Target | PRKD3 – Functional redundancy analysis for isoform compensation studies. | View PRKD3 Products |
| Pathway Partner | Protein Kinase C Epsilon (PKCε) – Upstream activator for PRKD1 activation assays. | View PRKCE Products |
| Related Target | PRKCA (PKCα) – Upstream regulator and structural homolog for off-target profiling. | View PRKCA Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PRKD1 vs PRKD2/3) | Homolog panel proteins strictly verified by mass spec (>95% purity); sequence alignment confirmed for selectivity screening. |
| Resistance Mutation Screening | D765N (Gatekeeper) mutant available; active site variants for inhibitor binding studies. |
| Activation State Detection | Phospho-specific antibodies (pSer916/pSer744) for functional readouts; HEK293 expressed native proteins. |
| Isoform Compensation Studies | Matched PRKD1/2/3 triple knockdown reagents available for redundancy analysis. |
| Off-Target Kinase Toxicity | High-purity (>95%) active recombinant kinases for accurate IC50 determination across kinase panel. |
| Lack of Reliable Cellular Controls | Lentivirus-generated stable cell lines for physiological readout. |
| False Positives in Screening | Validated siRNA included for specificity checks and genetic validation. |
Global Clinical Landscape & Future Outlook
The PRKD1 inhibitor landscape is transitioning from early exploratory studies in prostate and breast oncology toward targeted small molecule development with emphasis on isoform-selective profiles. As first-generation pan-PKD inhibitors face challenges with compensatory PRKD2/3 upregulation, the next wave of R&D prioritizes precision selectivity and combination regimens with PI3K/AKT pathway inhibitors. The emerging role of PRKD1 in cardiac hypertrophy and inflammatory signaling positions the target for expansion beyond oncology into cardiovascular and immunological indications. Major players such as Novartis and Basilea Pharmaceutica have contributed to early-stage kinase programs, while emerging biotechs focus on allosteric modulators and PROTAC degraders to bypass resistance. Additionally, known somatic mutations (e.g., rs1383618278 in colorectal cancer, rs1057519636 in CHDED, and rs55852813) underscore the genetic relevance of PRKD1 in disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (ATP-competitive) | Cancer Research Institutes, Novartis, Basilea Pharmaceutica | Prostate Cancer, Breast Cancer, Solid Tumors, Cardiac Hypertrophy | Active Kinase Domain proteins with validated ATP-binding capacity; High-purity (>95%) for IC50 determination; Isoform panel for selectivity evaluation. |
| Allosteric Inhibitors | Early Discovery Programs, Academic Consortia | Cardiac Hypertrophy, IBD | Full-length PRKD1 (HEK293 expressed) for conformational binding studies; Lentivirus for stable cell lines. |
| Targeted Protein Degradation (PROTAC) | Emerging Biotechs, Academic Consortia | Refractory Cancers, Resistance Cancers | Mutant PRKD1 constructs (D765N, etc.) for degradation resistance profiling; Endogenous/overexpression cell lines. |
| Gene Therapy / RNAi | Academic Spin-offs | Cardiovascular Disease | Knockdown validation (need high-specificity antibodies) and lentiviral delivery. |
Live PRKD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: